Pfizer, Inc. · NYSE:PFE
Pfizer — Cowen and Company 38th Annual Health Care Conference 2018
6 slides from Pfizer's conference presentation, Mar 14, 2018
Slide 1: Cowen and Company Health Care Conference: Pfizer Oncology
Cowen and Company Health Care Conference Pfizer Oncology Andy Schmeltz Global President, Pfizer Oncology March 14, 2018
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes forward-looking statements about, among other things, Pfizer’s oncology in-line products and product candidates, including anticipated regulatory submissions, approvals, performance and potential benefits of Pfizer's oncology products and product
Slide 3: Pfizer Oncology Growth Trajectory
Pfizer Oncology Growth Trajectory Growing in-line portfolio fueled by IBRANCE & XTANDI with potential for multiple launches on the horizon Mindset Opportunistic & Niche Growth & Leadership Revenue $B DACOMITINIB LORLATINIB GLASDEGIB TALAZOPARIB 2010 2011 2012 2013 2014 2015 2016 2017 2018E* 2019E* 2
Slide 4: A Rich Oncology Pipeline
A Rich Oncology Pipeline as of February, 2018 Cell Cycle & Angiogenesis Immunotherapy Metabolism Cell Signal Antibody Drug Therapeutic Transduction / Conjugate Vaccine Oncogenic Driver Anti-MCSF (PD-360324)(A626) Anti-PD1 OX-40 avelumab* bosutinib* (PF-06801591)(B801) (PF-04518600)(B060) NSCLC, Ovar
Slide 5: Focused to Realize Our Vision
Focused to Realize Our Vision To Be a Leader in Oncology by Speeding Cures and Accessible Breakthrough Medicines to Patients, Redefining Life with Cancer Key Focus Areas IBRANCE & Pipeline XTANDI* • Partner with key • Talazoparib: PARP • Innovative and stakeholders in the inhibitior meaningful patie
Slide 6: Q&A
Q&A Andy Schmeltz Global President, Pfizer Oncology
Pfizer — Cowen and Company 38th Annual Health Care Conference 2018 on 6ix